2-[4-(3-Chlorophenyl)piperazin-1-yl]-1-phenylethan-1-one

Catalog No.: 
ACCOLX687
CAS No.: 
250714-00-2
Molecular Formula: 
C18H19ClN2O
Molecular Weight: 
314.82
2-[4-(3-Chlorophenyl)piperazin-1-yl]-1-phenylethan-1-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$180.00InquiryInquiry
1g95%$567.00InquiryInquiry
5g95%$2807.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-[4-(3-Chlorophenyl)piperazin-1-yl]-1-phenylethan-1-one
IUPAC Name2-(4-(3-chlorophenyl)piperazin-1-yl)-1-phenylethan-1-one
MDL No.MFCD00141052
Molecular FormulaC18H19ClN2O
Molecular Weight314.82
SMILESO=C(C1=CC=CC=C1)CN2CCN(C3=CC=CC(Cl)=C3)CC2
InChI KeyNYVAYBJBTHCYHS-UHFFFAOYSA-N
Synonym2-[4-(3-CHLOROPHENYL)PIPERAZINO]-1-PHENYL-1-ETHANONE;2-[4-(3-chlorophenyl)piperazin-1-yl]-1-phenylethanone;Ethanone, 2-[4-(3-chlorophenyl)-1-piperazinyl]-1-phenyl-
CAS No.250714-00-2

Synthetic Route by SureRoute

1. ACCOLX687 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCOLX687 route product structure diagram
    ACCOLX687250714-00-2
Inquiry

2. ACCOLX687 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCOLX687 route product structure diagram
    ACCOLX687250714-00-2
Inquiry

3. ACCOLX687 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACCOLX687 route product structure diagram
    ACCOLX687250714-00-2
Inquiry

Comments (0)